Latest in bladder cancer from the second half of 2025

I-DXd shows strong brain metastasis responses in extensive-stage small cell lung cancer with manageable safety

Tarlatamab improves symptoms and QoL over chemo in previously treated SCLC

Tarlatamab improves survival over chemo in 2L SCLC regardless of prior immunotherapy or chemo

Temab-A plus bevacizumab shows promising response rates in advanced colorectal cancer

ESMO 2025: Latest developments in endometrial cancer

ESMO 2025: Precision medicine in bladder cancer

ESMO 2025: Highlights and analysis

PRAME-targeted TCR therapy shows high response rates in metastatic uveal melanoma

Best practice in precision medicine for prostate cancer

ctDNA test guides post-surgical immunotherapy for muscle-invasive bladder cancer

Visugromab plus nivolumab significantly increases pathologic response in muscle-invasive bladder cancer